LUPKYNIS (voclosporin)
FDA approved
Oral therapy for adult patients with active lupus nephritis; the company states it is the first FDA-approved oral therapy for this indication, introduced January 2021.
Learn more
Aurinia Pharmaceuticals
Biotechnology & Life SciencesNasdaq: AUPHEdmonton, AB
Edmonton-based biopharmaceutical company focused on therapies for autoimmune diseases, marketing LUPKYNIS (voclosporin) for active lupus nephritis.
Canadian innovation builds a brighter tomorrow.
About
Source: auriniapharma.comAurinia Pharmaceuticals describes itself as a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It introduced LUPKYNIS (voclosporin) in January 2021, which its own site calls the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, and is developing aritinercept, a dual BAFF and APRIL inhibitor.
Reported FY2025 net product sales of $271.3M, up 25% year over year, on total revenue of $283.1M, up 20%. auriniapharma.com
Reported FY2025 net income of $287.2M, against $5.8M in 2024, and year-end cash and investments of $398.0M. auriniapharma.com
Guided FY2026 net product sales of $305M to $315M and plans to begin a clinical study in an additional autoimmune disease in the first half of 2026. auriniapharma.com
Its FY2025 annual report states 128 full-time equivalent employees as of February 25, 2026, and that it is an Alberta, Canada corporation. sec.gov
Products & Services
Company site: auriniapharma.comProducts Aurinia Pharmaceuticals publishes on its own site. Each card links to the page it was taken from.
Aritinercept
Phase 1
Dual BAFF and APRIL inhibitor for autoimmune diseases, listed at Phase 1 on the company pipeline.
Learn morePeople
Sourced from the company's own pages or announcements.
Kevin Tang
Chair of the Board and Chief Executive Officer
Ryan Cole
Chief Operating Officer
Michael Hearne
Chief Financial Officer
Thomas Wei
Chief Scientific Officer
Technology Focus
Company site: auriniapharma.comTerms the company uses about its own work.
Autoimmune disease therapeuticsCalcineurin inhibitorsLupus nephritisBAFF and APRIL inhibitionOral small molecule therapy
Similar Companies
Other companies in Biotechnology & Life Sciences.
